Francois Mercier
Francois Mercier
F. Hoffmann-La Roche
Verified email at
Cited by
Cited by
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
K Selmaj, DKB Li, HP Hartung, B Hemmer, L Kappos, MS Freedman, ...
The Lancet Neurology 12 (8), 756-767, 2013
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G Francis, L Kappos, P O’connor, W Collins, D Tang, F Mercier, JA Cohen
Multiple Sclerosis Journal 20 (4), 471-480, 2014
Rivastigmine exposure provided by a transdermal patch versus capsules
F Mercier, G Lefèvre, HL Aaron Huang, H Schmidli, B Amzal, ...
Current medical research and opinion 23 (12), 3199-3204, 2007
Evaluation of tumor size response metrics to predict survival in oncology clinical trials
R Bruno, F Mercier, L Claret
Clinical Pharmacology & Therapeutics 95 (4), 386-393, 2014
Using historical control information for the design and analysis of clinical trials with overdispersed count data
S Gsteiger, B Neuenschwander, F Mercier, H Schmidli
Statistics in Medicine 32 (21), 3609-3622, 2013
Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
E Gibiansky, C Petry, F Mercier, A Günther, A Herman, L Kappos, ...
British journal of clinical pharmacology 87 (6), 2511-2520, 2021
A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain
F Mercier, L Claret, K Prins, R Bruno
Pain and therapy 3, 31-44, 2014
Population pharmacokinetic analysis and exploratory exposure–bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A
S Retout, C Schmitt, C Petry, F Mercier, N Frey
Clinical Pharmacokinetics 59, 1611-1625, 2020
Association between tumor size kinetics and survival in patients with urothelial carcinoma treated with atezolizumab: implication for patient follow‐up
C Tardivon, S Desmée, M Kerioui, R Bruno, B Wu, F Mentré, F Mercier, ...
Clinical Pharmacology & Therapeutics 106 (4), 810-820, 2019
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
PN Morcos, E Nueesch, F Jaminion, E Guerini, JC Hsu, W Bordogna, ...
Cancer Chemotherapy and Pharmacology 82, 129-138, 2018
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
G Meneses-Lorente, D Bentley, E Guerini, K Kowalski, E Chow-Maneval, ...
Investigational New Drugs 39, 803-811, 2021
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients
L Claret, F Mercier, BE Houk, PA Milligan, R Bruno
Cancer chemotherapy and pharmacology 76, 567-573, 2015
Estimating time to disease progression comparing transition models and survival methods—An analysis of multiple sclerosis data
M Mandel, F Mercier, B Eckert, P Chin, RA Betensky
Biometrics 69 (1), 225-234, 2013
Lymphocytes and fingolimod-temporal pattern and relationship with infections
G Francis, L Kappos, P O'Connor, W Collins, L Zhang-Auberson, ...
NEUROLOGY 76 (9), A374-A374, 2011
Population pharmacokinetics of fingolimod phosphate in healthy participants
K Wu, F Mercier, OJ David, RL Schmouder, M Looby
The Journal of Clinical Pharmacology 52 (7), 1054-1068, 2012
Exposure–bleeding count modeling of emicizumab for the prophylaxis of bleeding in persons with hemophilia A with/without inhibitors against factor VIII
F Jonsson, C Schmitt, C Petry, F Mercier, N Frey, S Retout
Clinical Pharmacokinetics 60, 931-941, 2021
Characterization of dose‐response for count data using a generalized MCP‐Mod approach in an adaptive dose‐ranging trial
F Mercier, B Bornkamp, D Ohlssen, E Wallstroem
Pharmaceutical Statistics 14 (4), 359-367, 2015
Model‐based drug development in oncology: what's next?
R Bruno, F Mercier, L Claret
Clinical Pharmacology & Therapeutics 93 (4), 303-305, 2013
Bayesian inference using Hamiltonian Monte‐Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy
M Kerioui, F Mercier, J Bertrand, C Tardivon, R Bruno, J Guedj, S Desmée
Statistics in Medicine 39 (30), 4853-4868, 2020
Pharmacokinetics, pharmacodynamics and exposure-response analyses of ocrelizumab in patients with multiple sclerosis (N4. 001)
H Kletzl, E Gibiansky, C Petry, F Mercier, A Guenther, Q Wang, F Model, ...
Neurology 92 (15 Supplement), 2019
The system can't perform the operation now. Try again later.
Articles 1–20